This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Novo Nordisk Unveils New U.S. Headquarters

PLAINSBORO, N.J., April 19, 2013 /PRNewswire/ -- Advancing its commitment to patients and New Jersey, Novo Nordisk (NYSE: NVO) today unveiled its new U.S. headquarters. Located in Mercer County in Plainsboro, N.J., the world-class building is the result of a $225 million redevelopment project, which utilized an existing structure and sustainable materials to limit environmental impact. The public and private sectors collaborated on this redevelopment project, which created over 500 union construction jobs.

(Photo: http://photos.prnewswire.com/prnh/20130419/PH98005)

(Logo: http://photos.prnewswire.com/prnh/20110414/NY80976LOGO)

"Becoming a leading healthcare company requires not only the best people in the field, but a work environment that fosters collaboration," said Jurek Gruhn, president of Novo Nordisk's U.S. business. "Our new home provides our employees with the physical space and resources to fuel our continued commitment to provide the best possible solutions for diabetes patients in the United States."

On hand for the building's debut were state and local officials, including New Jersey Lieutenant Governor Kim Guadagno, U.S. Senator Bob Menendez, U.S. Representative Rush Holt, State Senate President Steve Sweeney, and Township of Plainsboro Mayor Peter Cantu as well as local organizations and community partners.

"The completion of this project and launch of Novo Nordisk's new headquarters is a milestone in the long and proud history of the life sciences industry here in New Jersey," said Lt. Governor Guadagno. "We are gratified that this great global company has reaffirmed its belief that our state is an ideal location for a fast-growing, research-based business to plant its flag.  The impact of Novo Nordisk's investment will continue well into the future as additional jobs are created for our skilled New Jersey workforce."

"The country's diabetes epidemic is a serious and growing threat in the state and in our communities," said Sen. Bob Menendez. "Novo Nordisk's new building and the work being done here represents hope for people with diabetes and those caring for loved ones with diabetes. We're proud that New Jersey is home to this innovation."

The redeveloped building was designed to promote innovation, teamwork, and employee wellness. Features include a state-of-the-art cafeteria, a one-mile scenic walking path, and special quiet focus areas where employees can work effectively. The redesigned headquarters showcases Novo Nordisk's dedication to its unique internal culture and commitment to employees' personal growth—values that have earned the company recognition on the FORTUNE " 100 Best Companies to Work For" and the NJBiz " Best Places to Work in New Jersey" lists in 2013.

"As an employee of Novo Nordisk for 13 years, I've had a first-hand view of our remarkable evolution in the U.S.," said Jill Webb, senior director of medical information at Novo Nordisk. "I'm motivated daily by my colleagues and their dedication to improve patient wellbeing – something that has never changed, even after 13 years. This new headquarters is an opportunity to make it even easier for employees to have a direct impact on driving Novo Nordisk's leadership."

Utilizing recycled and locally-sourced materials, the new U.S. headquarters is consistent with Novo Nordisk's Triple Bottom Line (TBL) approach to business. The LEED Silver certified campus is fully powered by renewable energy from wind, solar, and hydro sources – a feature that is expected to lead to a 30 percent reduction in energy costs.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs